Research
Energy balance
Among 7,493 members, rates of persistence and adherence to treatment were 60.8% and 60.1%, respectively.
Practitioners should note that adherence to GLP-1 therapies is moderate in this population.
StrongSupportsmedium confidence
Rates of persistence and adherence to treatment were 60.8% and 60.1%, respectively.
Why this rating
Based on a retrospective claims-based analysis of a large population.
Source
Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population
Katelyn Meyer et al. · Journal of Managed Care & Specialty Pharmacy · 2026
DOI 10.18553/jmcp.2026.32.3.271
cohort · n=7493
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Among a subgroup of members on tirzepatide, semaglutide, or with exposure to both, 86.5% of members had at least a 5% reduction in body weight from baseline at 6 months.Strong
- Member-specific factors associated with lower rates of persistence and adherence included male sex, age (<40 years), diabetes, and a lack of weight-related comorbidities.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →